Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates.

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. Abstract Text:

V M Anderson,J W Bartlett,N C Fox,L Fisniku,D H Miller,Valerie M Anderson,Jonathan W Bartlett,Nick C Fox,Leonora Fisniku,David H Miller,Valerie M Anderson,Jonathan W Bartlett,Nick C Fox,Leonora Fisniku,David H Miller,

Brain atrophy, thought to reflect neuroaxonal degeneration, may be considered an objective marker of disease progression in multiple sclerosis (MS). Our objective was to estimate sample sizes required for parallel group placebo-controlled trials of disease-modifying treatments in relapsing remitting MS (RRMS), using brain atrophy on MRI as the outcome measure. In addition, we investigated how brain atrophy measurement method and trial duration affect sample sizes. Thirtythree patients with RRMS and 16 controls had T1-weighted volumetric MR imaging acquired at baseline and up to six repeat timepoints (six monthly intervals). Brain atrophy was quantified between baseline and each repeat image using four methods: segmented brain volume difference, BBSI, SIENA and ventricular enlargement. Linear mixed models were fitted to data from each subject group and method. Sample size calculations were performed using mean and variance estimates from these models. For a 2 year trial, a treatment slowing atrophy rate by 30% required 123 subjects in each treatment arm if using SIENA to measure atrophy, 157 for the BBSI, 140 for ventricular enlargement and 763 for segmented brain volume difference. For a given effect size and method, sample sizes were statistically significantly reduced the longer the trial duration. Our estimations suggest that brain atrophy could provide an additional outcome measure to clinical assessment for monitoring treatment effects in RRMS although the relationship between atrophy and subsequent disability, and potential confounding factors to atrophy measurement must be further investigated.

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. Publishing Authors By Initials

VM Anderson,JW Bartlett,NC Fox,L Fisniku,DH Miller,VM Anderson,JW Bartlett,NC Fox,L Fisniku,DH Miller,VM Anderson,JW Bartlett,NC Fox,L Fisniku,DH Miller,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of neurology

VOLUME: 254

Page Numbers: 1588-94

Journal Abbreviation: J. Neurol.

ISSN: 0340-5354

DAY: 25

MONTH: 10

YEAR: 2007

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 423161

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates.

AFFILIATION: MS NMR Research Unit, University College London Institute of Neurology, Queen Square, London, WC1N 3BG, UK.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Neurol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates Related Publications

• Bone morphogenetic protein-2 (BMP-2) and transforming growth factor-beta1 (TGF-beta1) alter connexin 43 phosphorylation in MC3T3-E1 Cells.
• Bovine abortion and neonatal death associated with Ureaplasma diversum.
• Characterization of growth and osteogenic differentiation of rabbit bone marrow stromal cells.
• Clinical evaluation of respiratory function in newborn infants.
• Conducting research: practical steps.
• Embryo transfer techniques in handling repeat breeding cows.
• Examining the effects of alcoholism typology and AA attendance on self-efficacy as a mechanism of change.
• Fibroblast growth factor receptor-1 interacts with the T-cell receptor signalling pathway.
• HIV testing among young adults in the United States: associations with financial resources and geography.
• Importance of diet of dam and colostrum to the biological antioxidant status and parenteral iron tolerance of the pig.
• Magnetic resonance imaging of microvascular leakage induced by myocardial contrast echocardiography in rats.
• Measurements of the anisotropy of ultrasonic attenuation in freshly excised myocardium.
• Measuring the quality of medication administration.
• Overexpression of BMP-2 modulates morphology, growth, and gene expression in osteoblastic cells.
• Personal perspectives: an interview with William R. Miller.
• Prediction of fertility of bovine semen: Preliminary studies with the hamster egg penetration test.
• Predictors of unsafe injecting drug use.
• Relationship of sialic acid and fatty acid composition of brain gangliosides: breast-fed vs formula-fed infant.
• Requirement for a localized, IP3R-generated Ca2+ transient during the furrow positioning process in zebrafish zygotes.
• Serial passage of MC3T3-E1 cells alters osteoblastic function and responsiveness to transforming growth factor-beta1 and bone morphogenetic protein-2.
• Spirituality: the silent dimension in addiction research. The 1990 leonard ball oration.
• Streamlined synthesis of phosphatidylinositol (PI), PI3P, PI3,5P2, and deoxygenated analogues as potential biological probes.
• Structure and measurement of dimensions of risk for HIV transmission in injecting drug users.
• Substrate-dependent dihydroxylation of substituted cyclopentenes: toward the syntheses of carbocyclic sinefungin and noraristeromycin.
• Survival of equine embryos co-cultured with equine oviductal epithelium from the four- to eight-cell to the blastocyst stage after transfer to synchronous recipient mares.
• The electrocardiogram in congenital malformations of the heart.
• Topical hyperbaric oxygen and low-energy laser for the treatment of chronic ulcers.
• Transient expression of apoaequorin in zebrafish embryos: extending the ability to image calcium transients during later stages of development.
• Trials of vinorelbine and docetaxel in the treatment of advanced non small-cell lung cancer.
• Ultrastructural assessment of a blastocyst recovered from a cow with subclinical purulent endometritis.